Thus, the microbial Ag presenting course of MM-Th2-MM interactions—restricted by MHC class-II—may result in tumor development such that every factor involved in the system may be potential targets for new myeloma therapies and interventions. This evidence concerns the gene HLA-C and plasma cell myeloma.